Comment on FR Doc # 2026-10128

Summary: The Association for Accessible Medicine (AAM) opposes the proposed rule, arguing that the expansion of quota subcategories and reporting requirements will increase administrative complexity and reduce manufacturer flexibility, potentially exacerbating drug shortages. They urge the DEA to defer the rule, address underlying structural issues like staffing and processing delays, and adopt more collaborative, data-driven reforms to improve supply chain resilience.